Netherlocks partial stroke system meets SIL 3

Published: 29-Apr-2010
Manufacturing

According to FMEDA report by Exida, the Netherlocks partial stoke system FAITH (Fail Action Integrity Test Handling) is very reliable

The FMEDA report showed the Netherlocks partial stoke system FAITH (Fail Action Integrity Test Handling) to be very reliable, with 0 Fail Safe Detected, Fail Safe Undetected and Fail Dangerous Detected conditions recorded from the tests. For most cases, the FAITH is suitable for use in SIL3 applications.

The FAITH system makes it possible to carry out a manually initiated partial stroke test on ESD (Emergency Shut Down) valves during normal operation, without interrupting process flow. It limits, with mechanical stops, the angle of the stroke of the valve-actuator combination to a set percentage – ensuring the ESD valve ‘works’, without actually shutting down the operation. By operating mechanically rather than relying on electronic contacts or signals, reliability and simplicity is maximised.

An FMEDA (Failure Modes, Effects, and Diagnostic Analysis) assessment has been carried out by Exida on Netherlocks’ FAITH system. The product was subject to a thorough examination according to IEC 61508 to determine Probability of Failure on Demand (PFD) statistics for this device. The failure rates of the FAITH System must be added to the failure rates of the valve-actuator combination when determining the PFD AVG and Safe Failure Fraction (SFF) for the final element.

More details, a summary and the report itself are available to customers upon request from sales@netherlocks.com or at www.netherlocks.com.
See more

You may also like

Manufacturing

Two leading valve operation brands merge to form Sofis

Read more
Netherlocks and Smith Flow Control reveal new corporate identity

Trending Articles

  1. Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
  2. AI-designed drug product enters clinical development Phase I study of an AI-designed oral formulation sets a new standard in drug development
  3. Cutting-edge wiped film evaporator installation – non-tobacco nicotine products Successful system installation for a UK research and development facility developing and commercialising non-tobacco nicotine products using industry-leading evaporation equipment
  4. Why integrated outsourcing wins in modern drug development Aligning drug substance and drug product development within a single outsourcing model accelerates timelines, sharpens CMC decisions and reduces risk by enabling parallel workstreams and shared governance
  5. Precision-engineered glass reaction and distillation systems up to 150 litres Labtex supplies industry-leading glass reactors from DIEHM with bespoke automation, temperature control, stirring and vacuum capabilities

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

Two leading valve operation brands merge to form Sofis

Netherlocks and Smith Flow Control reveal new corporate identity
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration

CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
Manufacturing

Cutting-edge wiped film evaporator installation – non-tobacco nicotine products

Successful system installation for a UK research and development facility developing and commercialising non-tobacco nicotine products using industry-leading evaporation equipment
Manufacturing

Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe

After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
Subscribe now